Literature DB >> 26362279

Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.

Dario Cattaneo1, Salvatore Sollima2, Nitin Charbe1, Chiara Resnati2, Emilio Clementi3,4, Cristina Gervasoni5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26362279     DOI： 10.1007/s00228-015-1936-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).

Authors:  Kayo Waki; Yasuhiko Sugawara
Journal:  Biosci Trends       Date:  2011       Impact factor: 2.400

2.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Authors:  Mark S Sulkowski; Joseph J Eron; David Wyles; Roger Trinh; Jay Lalezari; Chia Wang; Jihad Slim; Laveeza Bhatti; Joseph Gathe; Peter J Ruane; Richard Elion; Fritz Bredeek; Robert Brennan; Gary Blick; Amit Khatri; Krystal Gibbons; Yiran B Hu; Linda Fredrick; Gretja Schnell; Tami Pilot-Matias; Rakesh Tripathi; Barbara Da Silva-Tillmann; Barbara McGovern; Andrew L Campbell; Thomas Podsadecki
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

3.  Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

Authors:  Dario Cattaneo; Diego Ripamonti; Cristina Gervasoni; Simona Landonio; Paola Meraviglia; Sara Baldelli; Valeria Cozzi; Serena Fucile; Emilio Clementi
Journal:  J Clin Pharmacol       Date:  2011-03-07       Impact factor: 3.126

Review 4.  Treatment of recurrent hepatitis C in liver transplant recipients.

Authors:  Norah A Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

5.  Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

Authors:  L Tricot; E Teicher; G Peytavin; D Zucman; F Conti; Y Calmus; B Barrou; C Duvivier; C Fontaine; Y Welker; C Billy; P de Truchis; M Delahousse; D Vittecoq; D Salmon-Céron
Journal:  Am J Transplant       Date:  2009-06-10       Impact factor: 8.086

6.  Natural history of recurrent hepatitis C.

Authors:  Marina Berenguer
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799

7.  Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.

Authors:  Yumi Hashiguchi; Akinobu Hamada; Takashi Shinohara; Kiyoto Tsuchiya; Hirofumi Jono; Hideyuki Saito
Journal:  Biochem Biophys Res Commun       Date:  2013-08-24       Impact factor: 3.575

Review 8.  Long-term efficacy and safety of raltegravir in the management of HIV infection.

Authors:  Michelle D Liedtke; C Ryan Tomlin; Staci M Lockhart; Misty M Miller; R Chris Rathbun
Journal:  Infect Drug Resist       Date:  2014-03-18       Impact factor: 4.003

9.  Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.

Authors:  Joseph J Eron; Jay Lalezari; Jihad Slim; Joseph Gathe; Peter J Ruane; Chia Wang; Richard Elion; Gary Blick; Amit Khatri; Yiran B Hu; Krystal Gibbons; Linda Fredrick; Melannie Co; Ronald D'Amico; Barbara Da Silva-Tillmann; Roger Trinh; Mark S Sulkowski
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

10.  Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Authors:  P Badri; S Dutta; E Coakley; D Cohen; B Ding; T Podsadecki; B Bernstein; W Awni; R Menon
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086
View more
  1 in total

1.  Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.

Authors:  Charles S Venuto; Yoninah S Cramer; Susan L Rosenkranz; Mark Sulkowski; David L Wyles; Daniel E Cohen; Jeffrey Schmidt; Beverly L Alston-Smith; Gene D Morse
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.